Zemplar is indicated in adult and paediatric patients 10 to 16 years of age for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease Stages 3 and 4. Zemplar is indicated in adult patients for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease Stage 5 in patients who are on haemodialysis or peritoneal dialysis.
A Phase IV clinical trial comparing the efficacy of Zemplar, from Abbott, against cinacalcet plus low-dose vitamin D in treating...